DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

Active, not recruiting

Conditions: Muscle-invasive Urothelial Carcinoma

First Posted Date: 2023-03-22

Last Posted Date: 2025-01-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT05779592

Locations: 🇯🇵
Local Institution, City, State, Japan

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: BMS-986447

First Posted Date: 2023-03-09

Last Posted Date: 2024-04-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05760937

Locations: 🇺🇸
Local Institution - 0001, Anaheim, California, United States

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Recruiting

Conditions: Psoriasis

Interventions: Drug: Apremilast
Drug: Deucravacitinib

First Posted Date: 2023-02-27

Last Posted Date: 2024-07-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1500

Registration Number: NCT05744466

Locations: 🇺🇸
Local Institution, Waltham, Massachusetts, United States

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder

Completed

Conditions: Urinary Bladder Neoplasms

First Posted Date: 2023-02-24

Last Posted Date: 2025-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 115

Registration Number: NCT05742867

Locations: 🇺🇸
Local Institution - 0001, Morrisville, North Carolina, United States

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Phase 2

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: BMS-986322
Other: Placebo

First Posted Date: 2023-02-16

Last Posted Date: 2024-06-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT05730725

Locations: 🇺🇸
Local Institution - 0008, Cleveland, Ohio, United States
🇺🇸
Local Institution - 0001, Los Angeles, California, United States
🇺🇸
Local Institution - 0016, Los Angeles, California, United States

and more 32 locations

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Mavacamten

First Posted Date: 2023-02-09

Last Posted Date: 2023-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT05719805

Locations: 🇺🇸
Local Institution - 0002, Saint Paul, Minnesota, United States
🇺🇸
Local Institution - 0001, Miami, Florida, United States

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Mezigdomide

First Posted Date: 2023-01-31

Last Posted Date: 2024-02-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05707390

Locations: 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸
PANAX, Miami Lakes, Florida, United States

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Phase 4

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2023-01-27

Last Posted Date: 2025-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 180

Registration Number: NCT05701995

Locations: 🇺🇸
Local Institution - 0006, Phoenix, Arizona, United States
🇺🇸
Local Institution - 0034, Scottsdale, Arizona, United States
🇺🇸
Local Institution - 0015, North Little Rock, Arkansas, United States

and more 35 locations

A Rollover Study of CC-122

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: CC-122
Drug: Dexamethasone

First Posted Date: 2023-01-18

Last Posted Date: 2024-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT05688475

Locations: 🇳🇱
Local Institution - 400, Amsterdam, Netherlands
🇯🇵
Local Institution - 500, Koto-ku, Tokyo, Japan
🇺🇸
Local Institution - 100, New York, New York, United States

and more 4 locations

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: MYK-224

First Posted Date: 2023-01-17

Last Posted Date: 2023-05-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT05686096

Locations: 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy